歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

已收盘 05-13 16:08:12

17.150

+0.250

+1.48%

最高17.190	最低16.300	成交量164.40万
今开17.080	昨收16.900	日振幅5.27%
总市值181.96亿	流通市值181.96亿	总股本10.61亿
成交额2,766万	换手率0.15%	流通股本10.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":17.15,"timestamp":1778659692004,"preClose":16.9,"halted":0,"volume":1644000,"delay":0,"changeRate":0.014792899408284025,"floatShares":1061000000,"shares":1061000000,"eps":-0.42686924468459997,"marketStatus":"已收盘","change":0.25,"latestTime":"05-13 16:08:12","open":17.08,"high":17.19,"low":16.3,"amount":27657827,"amplitude":0.052663,"askPrice":17.15,"askSize":3000,"bidPrice":17.04,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.4325208504639962,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":5,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":16.9,"openAndCloseTimeList":[[1778635800000,1778644800000],[1778648400000,1778659200000]],"volumeRatio":1.550257,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2634021349","title":"GIC Private Limited增持歌礼制药-B(01672)12.2万股 每股作价16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634021349?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1191","BK1161","GIC","BK4104","BK1574","EWH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0310800965.SGD","LU0315179316.USD","IE0008369823.USD","LU0314109678.HKD","LU0326950275.SGD","02269","LU0572944931.SGD","LU2488822045.USD","LU1366192091.USD","LU2125154935.USD","SG9999004220.SGD","LU1719994722.HKD","02359","LU0516423174.USD","LU2097828714.EUR","LU2242644610.SGD","BK1515","LU1242518857.USD","01276","01672","LU2045819591.USD","LU0455707207.USD","LU0203347892.USD","LU0359202008.SGD","LU0980610538.SGD","LU1506573853.SGD","LU2360032135.SGD","603259","LU0516422366.SGD","LU0307460666.USD","LU0170899867.USD","LU0098860793.USD","BK4504","IE00B031HY20.USD","01801","LU0072461881.USD","LU1226287792.SGD","01093","BK1191","LU1997244956.HKD","LU1023057109.AUD","LU1997245177.USD","LU0979878070.USD","LU2417539215.USD","BK1141","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180788271","title":"歌礼制药-B更新2026年4月股份变动月报，净增发行240,525股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180788271","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180788271?lang=zh_cn&edition=full","pubTime":"2026-05-07 11:35","pubTimestamp":1778124945,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年5月7日披露了截至2026年4月30日的股份变动月报。公告显示，公司本月注册股本维持7,000,000,000股普通股不变，面值均为每股0.0001美元，总额700,000美元。截至2026年4月30日，公司已发行普通股由上月底的1,061,130,320股增至1,061,370,845股，库存股份数目仍为7,084,210股，合并后当月末已发行股份总数为1,068,455,055股。根据公告，公司此前曾于2025年进行多次股份购回，合计购回800,000股与4,986,000股普通股，目前尚未注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633975038","title":"歌礼制药-B(01672)将携多个项目数据亮相第33届欧洲肥胖症大会(ECO 2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633975038","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633975038?lang=zh_cn&edition=full","pubTime":"2026-05-06 08:12","pubTimestamp":1778026375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，将在2026年5月12日至15日于土耳其伊斯坦布尔举行的第33届欧洲肥胖症大会上，以壁报形式展示多个项目。展示内容包括关于ASC47I期数据的壁报，其联合司美格鲁肽在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达111.8%;以及关于ASC36临床前数据的壁报，其在非人灵长类动物模型中的平均表观半衰期为32天，比petrelintide长6倍，在饮食诱导肥胖大鼠模型中减重效果较 petrelintide相对提升91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","01672","ECO","LU0997586861.USD","BK4144","BK1574","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631650806","title":"港股异动 | 歌礼制药-B(01672)早盘涨超3% 公司将携多个项目数据亮相ADA 2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2631650806","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631650806?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:34","pubTimestamp":1777520091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨超3%，截至发稿，涨2.06%，报16.85港元，成交额736.72万港元。消息面上，歌礼制药宣布，将在6月5日至8日于路易斯安那州新奥尔良举行的美国糖尿病协会2026年度科学会议上，以壁报形式展示多个项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK1161","VXUS","BK1515","01477","BK1574","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575201","title":"歌礼制药-B(01672)将携多个项目数据亮相美国糖尿病协会2026年度科学会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575201","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631575201?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:10","pubTimestamp":1777507846,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，将在2026年6月5日至8日于路易斯安那州新奥尔良举行的美国糖尿病协会(ADA)2026年度科学会议上，以壁报形式展示多个项目。展示内容包括ASC39(一款治疗肥胖症的类似eloralintide、具有选择性的强效口服小分子胰淀素受体激动剂)的临床前数据，其入选为最新突破(late breaking)壁报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1161","01477","BK1515","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110149823","title":"歌礼制药-B：2025年度代谢与免疫管线稳步推进，收入同比增58%至2,028万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110149823","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110149823?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:10","pubTimestamp":1777471844,"startTime":"0","endTime":"0","summary":"在截至2025年12月31日止年度，歌礼制药-B专注于代谢性疾病及免疫性疾病等创新药物研发，围绕小分子与多肽项目的管线布局取得多项进展。从财务表现来看，2025年度公司收入达到2,028万元人民币，较2024年度的1,283万元增长58.07%。研发成本投入从上一年度的3.02亿元人民币增加至4.09亿元人民币，行政开支为7,523.2万元人民币。年内亏损为3.60亿元人民币，相较上年度3.01亿元人民币扩大19.55%，基本及摊薄每股亏损为人民币37.01分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：2025年度代谢与免疫管线稳步推进，收入同比增58%至2,028万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332792","title":"歌礼制药-B(01672)宣布口服小分子GLP-1R激动剂ASC30治疗糖尿病的美国II期研究完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332792","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630332792?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:09","pubTimestamp":1777248561,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，其评估口服小分子GLP-1受体 激动剂ASC30治疗2型糖尿病的13周美国II期研究已完成入组。预计将于2026年第3季度获得该项治疗2型糖尿病的II期研究的顶线数据。由歌礼自主研发的ASC30是首款也是唯一一款正在临床研究中的、既可每日一次口服也可每月一次至每季度一次皮下注射的小分子GLP-1R完全偏向激动剂，用于肥胖症、糖尿病及其它代谢疾病的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","GLP","01672","01477","BK1191","BK4590","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1515","LU2242644610.SGD","159992","LU2097828631.EUR","09969","02637","LU0455707207.USD","BK1574","06978","06990","LU2097828714.EUR","LU2328871848.SGD","BK1583","LU2097828474.EUR","06855","LU2097828557.USD","01672","BK1191","LU0196878994.USD","LU2097828805.USD","01801","01477","BK1161","LU1969619763.USD","BK1589","LU0502904849.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股异动 | 歌礼制药-B(01672)午前涨超4% 核心管线ASC30即将启动III期注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896382?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","01672","01477","BK1191","BK4134","BK4585","BK1515","III","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628536739","title":"歌礼制药-B(01672)：股价突破前高在即，场外资金为何选择观望？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628536739","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628536739?lang=zh_cn&edition=full","pubTime":"2026-04-18 12:36","pubTimestamp":1776486970,"startTime":"0","endTime":"0","summary":"股价突破前高在即，场外资金却选择观望?但在3月30日，歌礼制药交出2025年成绩单后，二级市场却出现“三连阴”放缓了公司股价后续的上攻势头。导致歌礼制药在2025年“增收不增利”的主要原因在于当期研发费用暴增。并且根据最新信息，礼来Orforglipron已于今年4月1日获FDA批准上市，成为全球首个口服小分子非肽类GLP-1减重药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1515","BK1161","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628927838","title":"港股异动 | 歌礼制药-B(01672)午后涨近5% 股价逼近历史前高 GLP-1+胰淀素复方制剂启动临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2628927838","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628927838?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:28","pubTimestamp":1776407328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午后涨近5%，高见18.68港元，逼近历史前高18.75港元。消息面上，歌礼制药近日公告，口服小分子GLP-1受体激动剂与口服小分子胰淀素受体激动剂固定剂量复方制剂ASC30_39FDC全面启动临床开发。值得关注的是，这是全球首个公开宣布的口服小分子GLP-1与口服小分子胰淀素固定剂量复方制剂，标志着歌礼在代谢疾病领域的创新布局实现关键突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","BK1515","BK1191","01477","01672","GLP","BK4144","BK1574","BK4590","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179745077","title":"港股创新药概念股盘初走高！丽珠医药涨超4%，歌礼制药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179745077","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179745077?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:37","pubTimestamp":1775698645,"startTime":"0","endTime":"0","summary":"创新药概念股盘初走高，$丽珠医药(01513)$涨超4%，$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超3%，$翰森制药(03692)$、$信达$、生物(01801)$、$药明康德(02359)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c276b56633daca2a66332a5543287c45","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","01672","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196868335","title":"歌礼制药-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1196868335","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196868335?lang=zh_cn&edition=full","pubTime":"2026-04-08 12:22","pubTimestamp":1775622130,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年4月8日披露截至2026年3月31日的股份变动月报表。报告显示，公司本月内无新增发行股份，已发行股份数量与上月保持一致，尚无完成注销的购回股份。截至3月31日，已发行股份总数为1,061,130,320股，库存股份为7,084,210股，两项合计1,068,214,530股，均与上月相同。在股份期权方面，截至3月末，公司根据2019年和2025年购股权计划合计授出的期权数量有所调整，但本月并未因此新增发行股份或从库存股份转让股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625627937","title":"歌礼制药-B(01672)：每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2625627937","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625627937?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:34","pubTimestamp":1775561655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布已选定ASC30_39 FDC，即每日一次口服小分子GLP-1R激动剂ASC30与每日一次口服小分子胰淀素选择性胰淀素受体激动剂ASC39的固定剂量复方制剂，进行临床开发。“据我们所知，这是首个公开宣布的口服GLP-1与口服胰淀素复方制剂，选定这一固定剂量复方制剂是开发ASC30与ASC39新型潜在协同口服复方制剂治疗肥胖的重要一步。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01672","BK4144","01477","BK1191","GLP","BK1515","BK4590","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195482842","title":"歌礼制药宣布启动ASC30与ASC39固定剂量复方制剂临床开发，每日一次口服小分子GLP-1R激动剂联合胰淀素受体激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1195482842","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195482842?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:00","pubTimestamp":1775559640,"startTime":"0","endTime":"0","summary":"歌礼制药近日宣布，将正式推进其创新复方制剂ASC30与ASC39的临床开发计划。该固定剂量组合包含每日一次口服的小分子GLP-1受体激动剂ASC30，以及每日一次口服的小分子胰淀素选择性受体激动剂ASC39。这一双靶点疗法旨在通过协同作用机制提升代谢类疾病的治疗效果，标志着公司在代谢疾病领域创新药研发的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188388661","title":"异动解读 | 歌礼制药-B盘中大涨5.17%，GLP-1口服片临床结果积极提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1188388661","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188388661?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:58","pubTimestamp":1775015928,"startTime":"0","endTime":"0","summary":"歌礼制药-B今日盘中股价大幅上涨5.17%，引起了市场的广泛关注。消息面上，公司于近期发布了2025年度业绩公告。其中，ASC30小分子GLP-1每日一次口服片在治疗肥胖症和糖尿病的临床研究中表现出积极结果，在肥胖症患者中实现的体重下降高达7.7%。此外，公告显示，尽管研发投资同比大幅增加35.3%，但公司通过提升研发效率和管理效率，有效控制了亏损的扩大幅度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623875538","title":"歌礼制药-B(01672)发布年度业绩 股东应占亏损3.6亿元 同比扩大19.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623875538","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623875538?lang=zh_cn&edition=full","pubTime":"2026-03-31 22:32","pubTimestamp":1774967536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布截至2025年12月31日止年度业绩，该集团期内取得收入总额1.27亿元人民币，同比增加5.2%;公司权益股东应占亏损3.6亿元，同比扩大19.6%;每股基本亏损37.01分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191","BK1515","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620428166","title":"歌礼制药-B(01672)：口服小分子胰淀素受体激动剂ASC39在临床前模型中显示出类似eloralintide的胰淀素选择性与疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620428166?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:48","pubTimestamp":1773740894,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，本公司董事会宣布已选定对胰淀素具有选择性的强效口服小分子胰淀素受体激动剂ASC39作为临床开发候选药物。这些数据表明，相较于hCTR， ASC39对hAMY1R具有高度选择性，且ASC39对hAMY1R的选择性与eloralintide 相当。ASC39与eloralintide对hAMY1R的选择性比对hCTR的分别高40倍和64倍。在一项头对头饮食诱导肥胖大鼠研究中，与接受安慰剂给药的肥胖大鼠相比，ASC39每日口服给药显示出具有统计学显著性的体重下降，与eloralintide相当(见表1)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191","BK1515","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104277630","title":"歌礼制药-B计划于2026年第三季度向美国FDA提交ASC39口服片剂新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1104277630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104277630?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:48","pubTimestamp":1773740893,"startTime":"0","endTime":"0","summary":"歌礼制药-B近日披露重要研发进展，公司计划在2026年第三季度向美国食品药品监督管理局提交ASC39口服片剂的新药临床试验申请。这一时间节点的明确标志着该创新药物研发进程进入关键阶段，为后续临床开发奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":-0.0585},{"period":"3month","weight":0.0078},{"period":"6month","weight":0.4202},{"period":"1year","weight":1.8027},{"period":"ytd","weight":0.4838}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.0337},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.5,"avgChangeRate":0.009924},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}